Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - formoterol fumarate dihydrate, quantity: 6 microgram; beclometasone dipropionate, quantity: 200 microgram; glycopyrronium bromide, quantity: 12.5 microgram (equivalent: glycopyrronium, qty microgram) - inhalation, pressurised - excipient ingredients: ethanol absolute; norflurane; dilute hydrochloric acid - asthma trimbow 200/6/10 maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

imtrade australia pty ltd - metham-sodium - soluble concentrate - metham-sodium carbamate-dithiocarbamate active 510.0 g/l - mixed function pesticide - bulk potting soil | general agricultural use | lawn | seedbed | spot spraying | tobacco seedbed | bulk soil | spray - club root | fat hen - seed | fat hen - seedling | fungal diseases - fusarium spp. | general fungal disease | nematode/eelworm | onion weed | phytophthora soil fungus | prince of wales feather - seed | prince of wales feather - seedling | rhizoctonia soil fungus | sclerotinia rot | symphylid | verticillium wilt | wilt rootrot or damping off | winter grass - seed | winter grass - seedling | amaranthus cruentus | amaranthus powellii | amaranthus viridis | asphodel | damping-off | garden centipedes | onion grass | ptilotus exaltus | pythium root rot | pythium soil fungus | sclerotinia flower blight | sclerotinia fungal disease | sclerotinia root rot | sclerotinia soil fungus | seedhead | seedling root rot | soil fungi | symphylans | verticillium dahliae | verticillium soil fungus | white goosefoot seedling | white mould | wild onion | wilt - sclerotinia

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include ? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. fluticasone salmeterol cip haler 250/50 is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg (equivalent: salmeterol, qty 0.05 mg); fluticasone propionate, quantity: 0.5 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: ?patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids ?patients who are symptomatic on current inhaled corticosteroid therapy,for the symptomatic treatment of patients with severe copd (fev1 <50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone salmeterol ciphaler 500/50 is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ausrichter pty ltd - butorphanol base as butorphanol tartrate; benzethonium chloride - parenteral liquid/solution/suspension - butorphanol base as butorphanol tartrate alkaloid active 10.0 mg/ml; benzethonium chloride ammonium-quaternary other 0.1 mg/ml - analgesic+musculoskeletal - cat | dog | horse | bitch | castrate | cat - queen | cat - tom | colt | donkey | endurance horse | filly | foal | gelding | high - anaesthetic - local/general | analgesic | pre-anaesthetic | anaesthetic premedicant | antipyretic | colic | general anaesthetic | immobiliser | local anaesthetic | muscle relaxant | premedication | sedative | spasmolytic | tranquilliser | travel sickness

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 4.5 mg - tablet, modified release - excipient ingredients: calcium hydrogen phosphate; hypromellose; magnesium stearate; silicon dioxide - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 2.25 mg - tablet, modified release - excipient ingredients: hypromellose; silicon dioxide; calcium hydrogen phosphate; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 3 mg - tablet, modified release - excipient ingredients: magnesium stearate; hypromellose; silicon dioxide; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1.5 mg - tablet, modified release - excipient ingredients: silicon dioxide; hypromellose; magnesium stearate; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.375 mg - tablet, modified release - excipient ingredients: calcium hydrogen phosphate; hypromellose; silicon dioxide; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.